Skip to main content

Table 1 Summary of antibodies and virus strains used in the study.

From: Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones

A. mAbs used

Target on Env

4E10

MPER*

2F5

MPER*

2G12

V3 glycans†

b12

CD4bs†

PG9

V1/V2 loop†

PG16

V1/V2 loop†

B. env strains used for Pseudovirus

Clade

Subject identifier

Accession Number

Gender

Mode of Transmission

Fiebig Stage b

SF162

B

N.A.

EU123924

Male

N/A

VI

AC10.0.29

B

AC10.0

AY835446

Male

MSMa

III

REJO4541.67

B

REJO4541

AY835449

Male

HSX

II

RHPA4259.7

B

RHPA4256

AY835447

Female

HSX

≤ V

THRO4156.18

B

THRO4156

AY835448

Male

MSM

II

C. IMC of T/F strains

      

CH040.c

B

700010040

JN944939

Male

MSM

T/F IMCc

CH058.c

B

700010058

JN944940

Male

MSM

T/F IMCc

CH077.t

B

700010077

JN944941

Male

MSM

T/F IMCc

REJO.c

B

REJO4541

JN944943

Male

HSX

T/F IMCc

RHPA.c

B

RHPA4256

JN944944

Female

HSX

T/F IMCc

THRO.c

B

THRO4156

JN944947

Male

MSM

T/F IMCc

  1. A. Monoclonal antibodies used and respective target epitope on Env; * on gp41 and † on gp120
  2. B-C. Virus used: Pseudovirus (B) and Transmitted/Founders (T/F) IMCs (C).
  3. aMSM, men who have sex with men; HSX, heterosexual.
  4. bThe stage of HIV-1 infection, as defined by Fiebig et al. [15], at which samples were obtained.
  5. cT/F IMCs represent the genomes of the strains that initiated clinical infection in the respective subjects. For detailed description, see C. Ochsenbauer et al., [2].